Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
36.31 +0.35 (+0.97%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 36.31 unch (unch) 17:50 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
35.13
Day High
36.35
Open 35.20
Previous Close 35.96 35.96
Volume 1,287,800 1,287,800
Avg Vol 2,542,375 2,542,375
Stochastic %K 95.40% 95.40%
Weighted Alpha +50.40 +50.40
5-Day Change +2.44 (+7.19%) +2.44 (+7.19%)
52-Week Range 21.62 - 39.47 21.62 - 39.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,955,783
  • Shares Outstanding, K 189,856
  • Annual Sales, $ 221,900 K
  • Annual Income, $ -535,760 K
  • EBIT $ -593 M
  • EBITDA $ -587 M
  • 60-Month Beta 1.08
  • Price/Sales 31.06
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 55.17% ( -5.65%)
  • Historical Volatility 54.79%
  • IV Percentile 26%
  • IV Rank 13.39%
  • IV High 151.63% on 11/18/24
  • IV Low 40.25% on 07/23/24
  • Put/Call Vol Ratio 0.97
  • Today's Volume 5,196
  • Volume Avg (30-Day) 2,930
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 91,431
  • Open Int (30-Day) 93,959

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.95
  • Number of Estimates 6
  • High Estimate -0.69
  • Low Estimate -1.26
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -1,800.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.33 +28.15%
on 04/09/25
Period Open: 36.74
37.06 -2.04%
on 03/27/25
-0.44 (-1.18%)
since 03/25/25
3-Month
28.33 +28.15%
on 04/09/25
Period Open: 37.59
39.47 -8.02%
on 02/20/25
-1.28 (-3.42%)
since 01/24/25
52-Week
21.62 +67.92%
on 06/24/24
Period Open: 24.33
39.47 -8.02%
on 02/20/25
+11.98 (+49.22%)
since 04/25/24

Most Recent Stories

More News
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

BBIO : 36.31 (+0.96%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO : 36.31 (+0.96%)
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

BBIO : 36.31 (+0.96%)
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BBIO : 36.31 (+0.96%)
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BBIO : 36.31 (+0.96%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO : 36.31 (+0.96%)
BridgeBio Announces CFO Succession

BBIO : 36.31 (+0.96%)
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why

Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and...

NVDA : 111.01 (+4.30%)
BBIO : 36.31 (+0.96%)
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BBIO : 36.31 (+0.96%)
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

BBIO : 36.31 (+0.96%)
BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO : 36.31 (+0.96%)
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BBIO : 36.31 (+0.96%)
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BBIO : 36.31 (+0.96%)
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

BBIO : 36.31 (+0.96%)
Brian's Big Idea: Healthcare Stocks

One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines,...

VCYT : 32.23 (+0.28%)
HIMS : 28.09 (-0.18%)
BBIO : 36.31 (+0.96%)
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

BBIO : 36.31 (+0.96%)
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

BBIO : 36.31 (+0.96%)
Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

BAYRY : 6.6100 (+2.80%)
AZN : 69.57 (+0.03%)
$SPX : 5,525.21 (+0.74%)
BBIO : 36.31 (+0.96%)
PFE : 22.92 (+0.61%)
BridgeBio Pharma, Inc. Announces Positive CHMP Recommendation for Acoramidis for ATTR-CM Treatment in Europe

CHMP recommends acoramidis for EU approval based on positive Phase 3 study results, with a final decision expected soon.Quiver AI SummaryThe Committee for Medicinal Products for Human Use (CHMP) has recommended...

BBIO : 36.31 (+0.96%)
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO : 36.31 (+0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 37.95
2nd Resistance Point 37.15
1st Resistance Point 36.73
Last Price 36.31
1st Support Level 35.51
2nd Support Level 34.71
3rd Support Level 34.29

See More

52-Week High 39.47
Last Price 36.31
Fibonacci 61.8% 32.65
Fibonacci 50% 30.55
Fibonacci 38.2% 28.44
52-Week Low 21.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.